- Rising Utilization Without Male Factor: ICSI is increasingly performed solely for advanced maternal age, diminished ovarian reserve (DOR), and low oocyte yield despite normal semen parameters
- ASRM 2026 Committee Opinion: Routine universal ICSI offers no proven benefit in improving clinical pregnancy or live birth rates in non-male factor cases
- No Superiority in PGT-A Cycles: Modern genetic testing technologies (NGS) have weakened the rationale for mandatory ICSI in aneuploidy screening; PGT-M remains an exception
- Indication-Driven Medicine: Microinjection should be guided by semen quality, fertilization history, and specific genetic protocols rather than fear of fertilization failure
“We only retrieved two or three eggs. What if none fertilize with conventional insemination? Wouldn’t it be far safer to perform microinjection on every single one?”
For patients undergoing In Vitro Fertilization (IVF), the anxiety surrounding fertilization failure escalates dramatically when oocyte yield is low. For women with diminished ovarian reserve or advanced maternal age, every individual egg represents an immense physical and emotional investment. It feels intuitive that manually inserting a single sperm directly into the egg via Intracytoplasmic Sperm Injection (ICSI) would offer a decisive advantage over conventional IVF.
However, an updated Committee Opinion published by the American Society for Reproductive Medicine (ASRM) draws a definitive line against this practice: in the absence of male factor subfertility, routinely performing ICSI solely for advanced age, low ovarian reserve, or low oocyte yield does not improve live birth rates.
Understanding the Difference: Mechanical Injection vs. Natural Insemination
ICSI involves isolating a single morphologically normal spermatozoon and injecting it directly into the ooplasm of a mature metaphase II (MII) oocyte using a microscopic glass micropipette. In contrast, conventional IVF co-incubates the retrieved oocyte with tens of thousands of motile sperm in a culture droplet, allowing natural physiological selection, the acrosome reaction, and zona pellucida penetration to occur autonomously.
ICSI was originally engineered to overcome severe male-factor infertility—including profound oligoasthenoteratozoospermia, surgical sperm retrieval (TESE/PESA), or prior unexpected total fertilization failure (TFF). In those clinical contexts, it remains indispensable.
The problem lies in indication creep. In contemporary practice, ICSI is routinely applied to couples with entirely normal semen parameters simply due to maternal age, low egg numbers, unexplained infertility, or anticipated preimplantation genetic testing.
The ASRM emphasizes a fundamental clinical principle: a marginal reduction in fertilization failure does not automatically translate into a higher cumulative live birth rate.
Low Oocyte Yield: ICSI Does Not Improve Live Birth Rates
The psychological urge to choose ICSI is strongest when only a handful of eggs are retrieved. Yet clinical trials fail to validate this intuition:
- Randomized Studies in Low Yield ($\mathbf{<6}$ Oocytes): In trials comparing ICSI and conventional IVF among non-male factor patients yielding fewer than 6 oocytes, ICSI demonstrated no statistically significant advantage in fertilization rates, complete fertilization failure rates, embryonic morphological quality, or clinical pregnancy rates.
- Large-Scale European Cohort ($\mathbf{>4,800}$ Cycles): A study analyzing first-time IVF cycles across 15 European clinics stratified patients by the number of retrieved oocytes. Across all yield categories—including poor responders—ICSI yielded no significant improvement in average fertilization rate, embryo utilization rate, fresh live birth rate, or cumulative live birth rate compared to conventional insemination.
The clinical equation “Few eggs $\rightarrow$ fear of fertilization failure $\rightarrow$ ICSI yields more babies” is simply not supported by the medical literature.
Advanced Maternal Age and Diminished Ovarian Reserve
Clinicians historically hypothesized that with advancing maternal age, changes in the zona pellucida (such as hardening) or alterations in the ooplasm could impede spontaneous sperm penetration, providing a rationale for microinjection.
The ASRM’s comprehensive literature review found no consistent evidence that routine ICSI enhances live birth rates in patients with advanced maternal age (AMA) or poor ovarian response.
Consequently, the committee explicitly concluded that neither advanced female age nor diminished ovarian reserve serves as an independent clinical indication for routine ICSI when semen parameters are normal.
PGT-A vs. PGT-M: How Sequencing Technology Has Shifted the Paradigm
Preimplantation genetic testing has historically driven high rates of non-male factor ICSI.
- Historical Rationale: Embryologists preferred ICSI prior to embryonic biopsy to eliminate extraneous non-fertilizing sperm adhering to the outer zona pellucida, avoiding potential paternal DNA contamination during PCR amplification.
- Modern PGT-A with NGS: With high-throughput Next-Generation Sequencing (NGS) and trophectoderm biopsy techniques, the risk of clinically significant extraneous DNA contamination in aneuploidy screening is negligible. The ASRM noted that in non-male factor PGT-A cycles, ICSI fails to improve euploidy rates, usable blastocyst yield, or delivery rates.
- PGT-M (Single-Gene Disorders): The equation remains distinct for monogenic disease testing. Because single-gene diagnostics evaluate minute parental sequence variants, DNA micro-contamination can alter diagnostic fidelity. ICSI remains recommended for PGT-M based on individual laboratory assay validation.
Clinical Evidence Overview: ICSI Indications
| Clinical Scenario | Routine ICSI Indicated? | ASRM Recommendation & Evidence Summary |
| Severe Male Factor Infertility | Yes | Standard of care; significantly improves fertilization and live birth. |
| Prior Total Fertilization Failure (TFF) | Yes | Clinically indicated to prevent recurrent unfertilized cycles. |
| Cryopreserved Oocyte Warming | Yes | Recommended due to cryo-induced zona pellucida hardening. |
| Monogenic Testing (PGT-M) | Yes | Recommended to avoid paternal DNA contamination in single-gene PCR. |
| Low Oocyte Yield ($\mathbf{\le 5}$ Oocytes) | No | No demonstrated improvement in fertilization or cumulative live birth. |
| Advanced Maternal Age (AMA) | No | Lacks evidence of benefit; natural penetration mechanisms remain intact. |
| Aneuploidy Screening (PGT-A) | No | Modern NGS does not require ICSI when semen parameters are normal. |
| Unexplained Infertility | No | Conventional IVF achieves equivalent live birth rates at lower cost. |
The True Question: “Is There a Medically Justified Need for ICSI?”
The ASRM Committee Opinion is not an argument against ICSI itself, but a call to abandon indiscriminate, defensive overutilization.
Every medical procedure carries trade-offs. ICSI is technically invasive: stripping the surrounding cumulus-oocyte complex and penetrating the oolemma with an injection pipette carries an inherent oocyte mechanical damage and lysis rate of approximately 5% to 10%. For a patient with only two or three mature oocytes, losing an egg to injection trauma is a tangible procedural risk.
When semen parameters are normal and there is no history of fertilization arrest, reflexively choosing ICSI simply because eggs are few or maternal age is advanced does not improve the final odds of taking home a baby.
Treatment strategies should balance semen analysis findings, prior embryological outcomes, oocyte maturity, and specific genetic testing requirements rather than relying on routine procedural escalation.
Medical Source & Study Reference
- Guideline: Intracytoplasmic sperm injection for nonmale factor indications: a Committee opinion
- Issuing Body: Practice Committee of the American Society for Reproductive Medicine (ASRM)
- Journal: Fertility and Sterility, Volume 126, Pages 49–56 (2026; replacing the 2020 Committee Opinion).
※ This article provides general scientific and medical information and does not replace individualized clinical diagnosis or care. Insemination methods should be determined collaboratively with an attending reproductive endocrinologist and embryology laboratory based on semen analysis parameters, oocyte yield, previous cycle outcomes, and genetic testing objectives.
※ The images associated with this article were generated using generative AI (ChatGPT, OpenAI) as illustrative visual references and do not depict real individuals.
※ Copyright © 2026 THE FERTILITY NOTES. All rights reserved. Unauthorized reproduction, duplication, distribution, scraping, AI training, or data utilization of all content, including articles, photos, and images, is strictly prohibited and may result in legal liability.